You are here

  • Home
  • Archive
  • Volume 10, Issue 2
  • Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)

 

Online download statistics by month:

Online download statistics by month: February 2022 to August 2025

AbstractFullPdf
Feb 2022238424121060
Mar 2022578584244
Apr 2022399419193
May 2022312323144
Jun 2022436466173
Jul 2022259265104
Aug 2022325330133
Sep 2022325326132
Oct 2022287295107
Nov 2022260260116
Dec 202221521590
Jan 202316016075
Feb 202318618691
Mar 2023197199111
Apr 202317817965
May 202319319279
Jun 202319019082
Jul 202316616679
Aug 202315815846
Sep 202312012056
Oct 202313913954
Nov 202312612868
Dec 202314014192
Jan 2024757643
Feb 2024898937
Mar 202414814992
Apr 202411611773
May 2024868647
Jun 2024949361
Jul 20249910162
Aug 2024696946
Sep 202416816864
Oct 202414014058
Nov 202412612760
Dec 202411712171
Jan 2025737425
Feb 202515615775
Mar 202511911974
Apr 202512512548
May 2025848453
Jun 2025919130
Jul 2025110
Aug 2025110
Total971098414413